We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Allergy Therapeutics Plc | AGY | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.20 | 16:35:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.25 | 5.10 | 5.26 | 5.20 | 5.20 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/11/2024 21:23 by farmergeorge Let's hope AGY are heading in the right direction out of the tunnel. All have a good weekend. |
Posted at 16/11/2024 13:53 by farmergeorge Jimmy, one standout characteristic of AGY is that,continually, everything keeps getting pushed out into the future. Let's hope we live long enougth to benefit. |
Posted at 16/11/2024 08:33 by jimmyloser Banjo,I am very mindful of the situation. Without going into detail, I have a significant holding here in P.I. terms and have been both thankful and impressed at the way that small investors had been given the opportunity to participate by the new owners and the apologies we received recently. Before they took control this looked a lost cause. The current share price in laughable compared to where this should and could be heading with the blockbuster products and contacts they have. Obviously with the history here, people are just waiting for more supporting evidence but the recent fund raising was for me a strong indicator that all is currently on track and the prospects are deemed to be ‘rewardingR 2025 appears to be a very interesting prospect from an AGY perspective. Impo |
Posted at 08/11/2024 15:02 by vergeltung I hate to introduce a negative note to this up-beat exchange, but a couple of the items in this RNS really irritated me:• 'Revenue of £55.2m (2023: £59.6m) from commercial portfolio, with encouraging H2 performance showing first period of half-year growth since 2021. Full year revenue impacted by supply constraints to key markets of Germany and Spain.' We all know why there has been no period of half-year growth since 2021 - in October 2022, just when H1’22 making should have been at full spate, the management decided to initiate its “short-term pause in UK manufacturing to optimise quality systems and accelerate capacity improvements” - which precipitated non-supply of markets, the collapse of the share price, suspension from AIM and series of emergency financing measures of increasing cost which hit us all so hard. So well done, Llobet and crew, on eking out a 2% increase but that you should be 'encouraged' by this painfully slow recovery from your own self-imposed, catastrophically-tim • 'Implemented new Long Term Incentive Plan to align key leadership interests with long-term shareholder value creation and strategic objectives.' Amazingly this is being represented as an achievement! It means Llobet is now reset to the new share price environment, - options with an exercise price of 0.1p - that’s right 1/10 of a penny - meaning he will not suffer from the share price having gone from the 20-30p range to the 1-5p range as a consequence of his decisions and actions. He has 9.65m options worth nearly £500k. I hardly need point out that the rest of us would have had to invest in the equity funding at 1p - 10x his exercise price - to avoid complete wipe-out. And with the exercise price so low the options have value even if the price collapses. Some incentive! This makes me fear the board and management at AGY have learned no lessons from their lamentable performance since 2021 despite (finally!) recognising the effect it has had on minority shareholders. So yes, we do have a longer cash runway (at considerable cost) and the development portfolio does hold great potential, so we are just one announcement away from a 2x price movement - but it's high risk and surely we can do better than this team to deliver for shareholders? |
Posted at 06/11/2024 12:54 by totally banjo Well it's steady away with a 2% increase in revenue for H2 2024 with medical trials and approvals still all on track!Not an earth shattering set of results by any means but happy to hold and maybe add for the longer term. A bit from AGY broker —Upcoming catalysts: Potential share-price catalysts for investor attention, which we note could materialise over the next 12 to 18 months include: (i) European approval and launch of Grass MATA MPL; (ii) first-year top-line efficacy and safety data from the long-term G308 study; and (iii) further data from the phase I/II PROTECT potential blockbuster VLP Peanut programme. —Investment thesis: While we continue to envisage growth of AGY’s existing portfolio, the foundation of our enthusiasm and investment thesis remains long-term value creation, as the new products are rolled out globally and further clinical data become available. Both Grass MATA MPL and VPL Peanut could be on course to enter blockbuster (>$1bn) markets, and we believe both are likely to be very attractive to potential commercial partners. |
Posted at 30/10/2024 12:42 by vergeltung Thanks @coinbase - I'll try to work out how to get on that and hopefully understand the trading in AGY a bit better! |
Posted at 27/10/2024 11:28 by jimmyloser What an exciting time to be a shareholder in AGY. Impo/Dyor etcWith Prelim results imminent and likely to tell us about increased productivity and efficiency resulting in growth in sales as indicated in the recent funding RNS. We also have the much awaited marketing application for Grass Mata (see below) and the update in Q4 of the biomarker data (much awaited and see below) It has been a turbulent ride across several years, but hey ho, it has been interesting and educational. PROTECT – Peanut The preliminary results from the first two cohorts of peanut allergic patients assessing safety and efficacy are expected in Q4 2024. Allergy Therapeutics announces successful meetings with Paul Ehrlich Institut to enable MAA plans for Grass MATA MPL Collaborative meetings held with the Paul Ehrlich Institut (PEI) to discuss proposed Chemistry, Manufacture and Controls (CMC) and clinical packages in support of upcoming Grass MATA MPL Marketing Authorisation Application (MAA), on track for submission in Q4 2024 - By including patients from the US, the G306 and G309 trials were designed as supportive to enable a pathway for Biologics License Application (BLA) in the US 3 June 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces updates on progression of the Group's MAA preparation for Grass MATA MPL. Developing a comprehensive data package Positive regulatory discussions have been held with the PEI regarding the results of the pivotal G306 Phase III trial, as well as the data in support of CMC requirements and the subsequent regulatory pathway to national registration of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. During the meetings, key trial data from the pivotal G306 Phase III trial were shared, alongside supporting CMC data that the Group plans to use as the basis for the proposed marketing authorisation application. Feedback was constructive and PEI confirmed that, subject to the usual regulatory approval procedures and detailed data analysis, the Group may proceed with an MAA. As previously announced, the Group intends to submit an MAA in Q4 2024. Supportive of US strategy Completion of the G309 and G306 field studies represents a significant milestone in plans for registration in the US. Following an earlier successful end of phase 2 meeting with FDA, the subsequent studies were designed to support a pathway forward to BLA in the US with both G309 and G306 studies including US subjects and it is also planned to include US subjects in the upcoming paediatric study G308. As previously communicated, a specific requirement for FDA, will involve a further study known as G307 to meet the required total number of US subjects treated using the product intended for registration and the Group are planning for meetings with the FDA to agree a route forward. Immediate focus will be preparing the data package for national MAA in Q4 alongside exploration for potential collaborations for US expansion. Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We appreciate the supportive and helpful discussions with the PEI and are very pleased that preparations for the regulatory submission of our Grass MATA MPL immunotherapy candidate remain on track. Bringing Grass MATA MPL to this stage has been a huge undertaking for a company like us. After many years and significant investment, we are extremely encouraged by the possibility of bringing this state-of-the-art vaccine to the market, transforming the lives of millions of patients around the world." |
Posted at 18/10/2024 12:15 by totally banjo farmer g, there has been a lot going on in the background regarding their existing product range! As in increasing the manufacturing base to meet the demand which we hopefully will see progress in the upcoming preliminary results.The ongoing trials and approvals are the main points of interest and they are completely out of AGY's control! The results of which are massively transformational for AGY as a company, like hugely massive :-). This obviously takes time! |
Posted at 16/10/2024 12:01 by totally banjo The extension to the loan facility from January 2027 to October 2030 is very important for various reasons:Firstly as the CEO Manuel Llobet implies, it takes the pressure off AGY in moving forward knowing they have the funds to draw on. Grass MATA MPL starts the German approval stage (plan was Q4 2024) with results due roughly in mid/late 2025 and if granted will see this product being sold within the largest allergen immunotherapy market in Europe! This would then forward to a USA approval route which if successful gives access (est. 2027) to a $2bn market! VLP Peanut Programme, AGY are expecting the preliminary results of this trial during Q4 this year leading to FDA approvals, going to market....2028-2030? Revenues would be massive! Still lots of hurdles to overcome and we will get an update on the current product sales along with updates on the various trials and approvals with the preliminary results estimated to be published end of this month. Very exciting times, in my opinion |
Posted at 04/9/2024 10:24 by totally banjo The PROTECT trial estimated completion date is a few months into 2025 but this, I believe, is the follow up on subjects after the trial is finished.Therefore it is likely that we will get the results of the trial in Q4 2024 which will, if positive, give AGY exposure on the global stage which should be reflected in the share price I'm very positive for AGY future but it does need highlighting that the various on going trials will take time to become revenue generating. It is also quite possible AGY could be bought out before this time! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
